Akshai Lakhanpal
Internal Medicine · Plano, TXNPI 1700147683
Payments from drug & device makers
Across 124 payments — averaging $31.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$2K
- Novo Nordisk$491
- Amarin Pharma, Inc.$289
- Boehringer Ingelheim$166
- AstraZeneca$130
- GSK$121
- plus $522 from 17 others
What the payments were for
- Food & beverage$1,717100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 25 | $2,136 |
| Novo Nordisk | 28 | $491 |
| Amarin Pharma, Inc. | 15 | $289 |
| Boehringer Ingelheim | 9 | $166 |
| AstraZeneca | 9 | $130 |
| GSK | 8 | $121 |
| Merck | 7 | $111 |
| Bayer | 4 | $74 |
| Abbott | 3 | $46 |
| Amgen | 2 | $35 |
| Phadia US Inc. | 2 | $26 |
| Dexcom, Inc. | 1 | $25 |
| Nabriva Therapeutics, PLC | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Pfizer | 1 | $21 |
| Novartis | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $19 |
| Medtronic | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$110
How this compares
$3,853 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 90 | $125,414 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $49,449 |
| OzempicSemaglutide | 25 | $45,644 |
| MyrbetriqMirabegron | 16 | $20,542 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $11,615 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 107 | $3,546 |
| BreynaBudesonide/Formoterol Fumarate | 14 | $2,899 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,730 |
| Atorvastatin Calcium | 216 | $1,519 |
| Lidocaine | 14 | $1,203 |
| Rosuvastatin Calcium | 107 | $1,178 |
| Gabapentin | 56 | $1,149 |
| Fluticasone Propionate | 44 | $1,112 |
| Lisinopril | 168 | $922 |
| Tamsulosin Hcl | 33 | $800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $166 | $125,41490 claims |
| Novo NordiskOzempic | $491 | $45,64425 claims |
| AstraZenecaSymbicort | $130 | $11,61523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Plano
- Saumil MehtaPlano$5.4M
- Tanvir AhmadPlano$3.5M
- Sophia RahmanPlano$3.3M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.